MedTrace Logo

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

NCT00439270 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2014-03-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.

Conditions

Interventions

DRUG

Dasatinib

Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

DRUG

Docetaxel

Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2012-02-29
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439270 on ClinicalTrials.gov